Novartis eyes filings for leukaemia drug asciminib after phase 3 winA first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid Share XNovartis eyes filings for leukaemia drug asciminib after phase 3 winhttps://pharmaphorum.com/news/novartis-eyes-filings-for-leukaemia-drug-asciminib-after-phase-3-win/
CVS rolls out digital messaging for meds adherence after pilotUS pharmacy chain CVS Specialty has made its two-way messaging app available to 80% of eligible patients on Share XCVS rolls out digital messaging for meds adherence after pilothttps://pharmaphorum.com/news/cvs-rolls-out-digital-messaging-for-meds-adherence-after-pilot/
Cancer Research UK gives $4m funding to Glasgow Uni CML projectCancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to Share XCancer Research UK gives $4m funding to Glasgow Uni CML projecthttps://pharmaphorum.com/news/experimental-leukaemia-study-grant/
Pfizer leukaemia drug accepted by NICEBosulif is first drug to be funded following reassessment. Share XPfizer leukaemia drug accepted by NICEhttps://pharmaphorum.com/news/pfizer-leukaemia-drug-accepted-nice/